Research Study

A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Principal Investigator 
Alan Weiss

Overview

Body Locations and Systems 
Disorders and Conditions 
ClinicalTrials.gov# 
NCT01755767
Status 
Closed to Recruitment
Study Start/End 
Aug 11, 2014 to Mar 31, 2017
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Jo-Ann Ford, Study Coordinator
Phone 
604-875-5705
Email Address 
joann.ford@vch.ca
Purpose of Study 

The purpose of this study is to determine if tivantinib (ARQ 197) is effective in treating patients with MET diagnostic-high hepatocellular carcinoma (liver cancer) who have already been treated once with another therapy.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.